Scientific Advancements in Drug Development and Trials for Urothelial Carcinoma: Insights From the 2023 ASCO-GU Cancers Symposium.

Aging Dis · 2023 · PMC10676780 · PMID 37199595

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

IMVIGOR 130 phase III trial ( NCT02807636 ) reported final overall survival (OS) data, showing that improved OS with Atezolizumab plus platinum/ gemcitabine vs placebo plus platinum/gemcitabine did not reach statistical significance in patients with la-/mUC.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.